US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US20030157129A1
(en)
*
|
1995-06-23 |
2003-08-21 |
Smithkline Beecham Biologicals S.A. |
Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
|
US7078042B2
(en)
*
|
1995-09-15 |
2006-07-18 |
Uab Research Foundation |
Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
|
EP0909323B1
(en)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Helicobacter pylori bacterioferritin
|
FR2763244B1
(fr)
|
1997-05-14 |
2003-08-01 |
Pasteur Merieux Serums Vacc |
Composition vaccinale multivalente a porteur mixte
|
US20010016200A1
(en)
*
|
1998-04-23 |
2001-08-23 |
Briles David E. |
Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
|
NZ508927A
(en)
|
1998-05-22 |
2003-12-19 |
Ottawa Health Research Inst |
Methods and products for inducing mucosal immunity
|
US6797275B1
(en)
*
|
1998-12-04 |
2004-09-28 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
|
CA2365296A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Pierre Michel Desmons |
Vaccine
|
GB9925559D0
(en)
*
|
1999-10-28 |
1999-12-29 |
Smithkline Beecham Biolog |
Novel method
|
GB0108364D0
(en)
*
|
2001-04-03 |
2001-05-23 |
Glaxosmithkline Biolog Sa |
Vaccine composition
|
GB0022742D0
(en)
*
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
CA2881568C
(en)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from streptococcus groups a & b
|
GB2370770B
(en)
*
|
2001-01-03 |
2005-06-01 |
Simon Connolly |
Uses of Streptococcus Vaccines
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
EP2332581B1
(en)
|
2001-01-23 |
2015-07-01 |
Sanofi Pasteur Inc. |
Tri- or tetravalent meningococcal polysaccharide-CRM197 conjugate vaccine
|
PT1361890E
(pt)
|
2001-02-23 |
2011-06-07 |
Glaxosmithkline Biolog Sa |
FormulaƧƵes vacinais de influenza para distribuiĆ§Ć£o intradĆ©rmica
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0109297D0
(en)
*
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB0115176D0
(en)
*
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
NZ533428A
(en)
|
2001-12-12 |
2008-03-28 |
Chiron Srl |
Immunisation against chlamydia trachomatis
|
GB0130215D0
(en)
*
|
2001-12-18 |
2002-02-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2476626A1
(en)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticles with adsorbed polypeptide-containing molecules
|
DE60328481D1
(de)
*
|
2002-05-14 |
2009-09-03 |
Novartis Vaccines & Diagnostic |
Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
|
GB0302218D0
(en)
|
2003-01-30 |
2003-03-05 |
Chiron Sri |
Vaccine formulation & Mucosal delivery
|
WO2003094960A2
(en)
*
|
2002-05-14 |
2003-11-20 |
Chiron Srl |
Mucosal combination vaccines for bacterial meningitis
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
SI2351579T1
(sl)
|
2002-10-11 |
2017-05-31 |
Glaxosmithkline Biologicals Sa |
Polipeptidna cepiva za Å”iroko zaÅ”Äito proti hipervirulentnim meningokoknim linijam
|
WO2004035618A2
(en)
*
|
2002-10-15 |
2004-04-29 |
Intercell Ag |
Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
|
KR101130948B1
(ko)
|
2002-11-01 |
2012-03-30 |
źøė½ģģ¤ėÆøģ¤ķ“ė¼ģø ė°ģ“ģ¤ė”ģ§ģ¹¼ģ¦ ģģ¤.ģģ“. |
ź±“ģ”° ź³µģ
|
AU2003295520B8
(en)
|
2002-11-12 |
2011-05-19 |
The Brigham And Women's Hospital, Inc. |
Polysaccharide vaccine for Staphylococcal infections
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
EP1578954A4
(en)
|
2002-12-11 |
2010-08-11 |
Coley Pharm Group Inc |
5'-CPG NUCLEIC ACIDS AND USE METHOD
|
WO2004060396A2
(en)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenic compositions containing phospholpid
|
FR2850106B1
(fr)
|
2003-01-17 |
2005-02-25 |
Aventis Pasteur |
Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
|
CN101926988B
(zh)
*
|
2003-01-30 |
2014-06-04 |
čÆŗåē«čåčÆęęéå
¬åø |
ęå¤ē§ččēēčč”ęø
ē»ēåÆę³Øå°ę§ē«č
|
JP5102487B2
(ja)
|
2003-03-07 |
2012-12-19 |
ćÆć¤ć¹ć»ćć¼ć«ćć£ć³ć°ćŗć»ć³ć¼ćć¬ć¤ć·ć§ć³ |
é¢å
ęęć«åƾććå
ē«åć®ććć®å¤ē³ććć¦ēčč”Øé¢ä»ēå åćć£ćŖć¢ćæć³ććÆč³Ŗę„åä½
|
ES2295836T3
(es)
*
|
2003-03-13 |
2008-04-16 |
Glaxosmithkline Biologicals S.A. |
Procedimiento de purificacion de citolisina bacteriana.
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
US9107831B2
(en)
|
2003-06-02 |
2015-08-18 |
Novartis Vaccines And Diagonstics, Inc. |
Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
ATE506963T1
(de)
*
|
2003-10-02 |
2011-05-15 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen meningitis
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
PL1740217T3
(pl)
|
2004-04-30 |
2012-03-30 |
Novartis Ag |
Szczepienie koniugatem meningokokowym
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
US7444197B2
(en)
*
|
2004-05-06 |
2008-10-28 |
Smp Logic Systems Llc |
Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
EP1765313A2
(en)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Compounds for immunopotentiation
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PT2682126T
(pt)
|
2005-01-27 |
2017-02-28 |
Children`S Hospital & Res Center At Oakland |
Vacinas de vesĆcula com base em agn1870 para proteĆ§Ć£o de amplo espetro contra doenƧas causadas por neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
HUE030881T2
(en)
|
2005-02-18 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
|
GB0505518D0
(en)
*
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
US20070184072A1
(en)
|
2005-04-08 |
2007-08-09 |
Wyeth |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7955605B2
(en)
|
2005-04-08 |
2011-06-07 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
US7709001B2
(en)
*
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
CN104815327A
(zh)
|
2005-04-08 |
2015-08-05 |
ę ę°ęéč“£ä»»å
¬åø |
å¤ä»·čŗēēčå¤ē³-čē½č“Øē¼åē©ē»åē©
|
EP2329843A3
(en)
|
2005-04-18 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Expressing Hepatitis B Virus surface antigen for vaccine preparation
|
HUE031380T2
(en)
|
2005-06-27 |
2017-07-28 |
Glaxosmithkline Biologicals Sa |
A method for producing vaccines
|
AU2006286228A1
(en)
|
2005-09-01 |
2007-03-08 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Multiple vaccination including serogroup C meningococcus
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
EP2360175B1
(en)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus and Sapovirus virus-like particles (VLPs)
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
ę°ē©ēµåē©
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2808919C
(en)
|
2005-12-22 |
2016-04-19 |
Glaxosmithkline Biologicals S.A. |
Streptococcus pneumoniae capsular saccharide vaccine
|
ZA200805602B
(en)
*
|
2006-01-17 |
2009-12-30 |
Arne Forsgren |
A novel surface exposed haemophilus influenzae protein (protein E; pE)
|
CN101024079B
(zh)
*
|
2006-02-17 |
2012-02-01 |
ē¦å·ęęēē©å·„ēØęéå
¬åø |
čŗēé¾ēčå¤ē³-å¤ččē½ē»åē«čåå¶å¤ę¹ę³
|
KR101947794B1
(ko)
*
|
2006-03-17 |
2019-02-13 |
ė ź±°ė²ėؼķø ģ¤ėø ė ģ ėģ“ķ°ė ģ¤ķ
ģ“ģø ģ¤ėø ģė©ė¦¬ģ¹“ ģģ¦ ė ķė¦¬ģ ķ°ė ė°ģ“ ė ģøķ¬ė¬ķ
ė¦¬ ģ¤ėø ė ėķķøėؼķø ģ¤ėø ķ¬ģ¤ ģ¤ė ķ“ėؼ ģė¹ģģ¦ |
ė³µķ© ė¤ź° ė©“ģģģ± ģ½ģ„¬ź²ģ“ķøģ ģ ģ”° ė°©ė²
|
ES2670231T3
(es)
|
2006-03-22 |
2018-05-29 |
Glaxosmithkline Biologicals S.A. |
RegĆmenes para inmunizaciĆ³n con conjugados meningocĆ³cicos
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
US10828361B2
(en)
|
2006-03-22 |
2020-11-10 |
Glaxosmithkline Biologicals Sa |
Regimens for immunisation with meningococcal conjugates
|
ES2376492T3
(es)
|
2006-03-23 |
2012-03-14 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores.
|
AU2007233705B2
(en)
*
|
2006-03-30 |
2010-12-23 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
TWI494124B
(zh)
*
|
2006-03-30 |
2015-08-01 |
Glaxosmithkline Biolog Sa |
å
ē«åēµåē©
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
US8808707B1
(en)
|
2006-05-08 |
2014-08-19 |
Wyeth Llc |
Pneumococcal dosing regimen
|
US20100015168A1
(en)
*
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
MX2009003730A
(es)
*
|
2006-10-10 |
2009-04-22 |
Wyeth Corp |
Purificacion de polisacaridos de streptococcus pneumoniae tipo 3.
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
DK2167121T3
(en)
|
2007-06-26 |
2015-11-23 |
Glaxosmithkline Biolog Sa |
A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
BRPI0816689B1
(pt)
|
2007-09-12 |
2021-08-24 |
Novartis Ag |
ComposiĆ§Ć£o de vacina, kit e mĆ©todo para a confecĆ§Ć£o de uma composiĆ§Ć£o de vacina para a prevenĆ§Ć£o ou tratamento de infecĆ§Ć£o por streptococcus pyogenes
|
SI2200642T1
(sl)
|
2007-10-19 |
2012-06-29 |
Novartis Ag |
Formulacije meningokoknega cepiva
|
EP2217250A4
(en)
|
2007-11-09 |
2011-01-05 |
California Inst Of Techn |
IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ601543A
(en)
|
2007-12-21 |
2013-03-28 |
Novartis Ag |
Mutant forms of streptolysin o
|
EP2252326A4
(en)
*
|
2008-02-01 |
2012-08-29 |
Newcastle Innovation Ltd |
VACCINE COMPOSITIONS
|
EP2886551A3
(en)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningococcal fhbp polypeptides
|
US9511131B2
(en)
|
2008-03-10 |
2016-12-06 |
Children's Hospital & Research Center Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
RU2532911C2
(ru)
|
2008-07-21 |
2014-11-20 |
ŠŠ·Šµ ŠŃŠøŃ
ŃŠ¼ ŠŠ½Š“ Š£ŠøŠ¼ŠµŠ½'Š Š„Š¾ŃŠæŠøŃŠ°Š», ŠŠ½Šŗ. |
Š”ŠæŠ¾ŃŠ¾Š±Ń Šø ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠø, Š¾ŃŠ½Š¾ŃŃŃŠøŠµŃŃ Šŗ ŃŠøŠ½ŃŠµŃŠøŃŠµŃŠŗŠøŠ¼ Š±ŠµŃŠ°-1,6-Š³Š»ŃŠŗŠ¾Š·Š°Š¼ŠøŠ½Š¾Š»ŠøŠ³Š¾ŃŠ°Ń
Š°ŃŠøŠ“Š°Š¼
|
AU2009309416B2
(en)
|
2008-10-27 |
2015-05-28 |
Glaxosmithkline Biologicals S.A. |
Purification method
|
NZ592977A
(en)
|
2008-12-09 |
2013-01-25 |
Pfizer Vaccines Llc |
IgE CH3 PEPTIDE VACCINE
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
AU2009329193A1
(en)
|
2008-12-17 |
2011-07-14 |
Novartis Ag |
Meningococcal vaccines including hemoglobin receptor
|
CA2748788C
(en)
|
2009-01-05 |
2021-02-09 |
Epitogenesis Inc. |
The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
EP2411048B1
(en)
|
2009-03-24 |
2020-05-06 |
GlaxoSmithKline Biologicals SA |
Adjuvanting meningococcal factor h binding protein
|
RU2555757C2
(ru)
|
2009-03-24 |
2015-07-10 |
ŠŠ¾Š²Š°ŃŃŠøŃ ŠŠ³ |
ŠŠ¾Š¼Š±ŠøŠ½Š°ŃŠøŠø Š¼ŠµŠ½ŠøŠ½Š³Š¾ŠŗŠ¾ŠŗŠŗŠ¾Š²Š¾Š³Š¾ ŃŠ°ŠŗŃŠ¾Ń Š½-ŃŠ²ŃŠ·ŃŠ²Š°ŃŃŠµŠ³Š¾ Š±ŠµŠ»ŠŗŠ° Šø ŠæŠ½ŠµŠ²Š¼Š¾ŠŗŠ¾ŠŗŠŗŠ¾Š²ŃŃ
ŃŠ°Ń
Š°ŃŠøŠ“Š½ŃŃ
ŠŗŠ¾Š½ŃŃŠ³Š°ŃŠ¾Š²
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
čå
°ē“ å²åÆäøå
č±ę©ēē©ęéå
¬åø |
ēØäŗå
ē«ę„ē§ä»„ęµå¾”éé»č²č”čēčēē»åē©
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
US8568735B2
(en)
|
2009-06-22 |
2013-10-29 |
Wyeth Llc |
Immunogenic compositions of Staphylococcus aureus antigens
|
MY158231A
(en)
|
2009-06-22 |
2016-09-15 |
Wyeth Llc |
Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
|
US8647621B2
(en)
|
2009-07-27 |
2014-02-11 |
Fina Biosolutions, Llc |
Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
|
NZ618391A
(en)
|
2009-07-30 |
2015-07-31 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
EP2470204B1
(en)
|
2009-08-27 |
2015-12-16 |
GlaxoSmithKline Biologicals SA |
Hybrid polypeptides including meningococcal fhbp sequences
|
KR101660578B1
(ko)
|
2009-09-03 |
2016-09-27 |
ķģ“ģ ė°±ģ ģ¤ ģģģØ |
ļ¼°ļ½ļ½ļ½ļ¼ ė°±ģ
|
KR20120081587A
(ko)
|
2009-09-10 |
2012-07-19 |
ė
øķė„“ķ°ģ¤ ģź² |
źø°ė ģ§ė³ģ ėķ ģ”°ķ© ė°±ģ
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptĆdeos de modificaĆ§Ć£o meningocĆ³cica fhbp"
|
AU2010310919B2
(en)
|
2009-10-30 |
2015-05-07 |
Glaxosmithkline Biologicals S.A. |
Purification of Staphylococcus aureus type 5 and type 8 capsular saccharides
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
US9044517B2
(en)
*
|
2009-12-17 |
2015-06-02 |
Fina Biosolutions, Llc |
Activation of polysaccharides via the cyanylating agent, 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), in the preparation of polysaccharide/protein conjugate vaccines
|
WO2011077309A2
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Vaccines Llc |
Vaccine compositions
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
EP2552942B1
(en)
|
2010-03-30 |
2017-12-27 |
Children's Hospital & Research Center at Oakland |
Factor h binding proteins (fhbp) with altered properties and methods of use thereof
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2555753B1
(en)
|
2010-04-07 |
2018-08-01 |
California Institute of Technology |
Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
|
WO2011146910A1
(en)
*
|
2010-05-20 |
2011-11-24 |
Round June L |
Antigen specific tregs and related compositions, methods and systems
|
HUE048398T2
(hu)
*
|
2010-06-04 |
2020-07-28 |
Wyeth Llc |
VakcinakĆ©szĆtmĆ©nyek
|
EP2575868A1
(en)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Ige ch3 peptide vaccine
|
WO2011154863A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Her-2 peptides and vaccines
|
WO2011161653A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
EP2667852B1
(en)
|
2011-01-27 |
2016-11-09 |
GlaxoSmithKline Biologicals SA |
Adjuvant nanoemulsions with crystallisation inhibitors
|
CA2828844C
(en)
|
2011-03-02 |
2020-07-14 |
Novartis Ag |
Combination vaccines with lower doses of antigen and/or adjuvant
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
US10357568B2
(en)
|
2011-03-24 |
2019-07-23 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with phospholipids
|
EP2511295A1
(en)
|
2011-04-15 |
2012-10-17 |
Institut National De La Sante Et De La Recherche Medicale |
Compositions for preventing and/or treating an infection by an HIV-1 virus
|
EA030920B1
(ru)
|
2011-05-06 |
2018-10-31 |
ŠŠµŃŃ ŠŠµŠ½Š½Š°Š“ŃŠµŠ²ŠøŃ ŠŠŠŠ ŠŠ |
ŠŠŗŠ·Š¾ŠæŠ¾Š»ŠøŃŠ°Ń
Š°ŃŠøŠ“ Š±Š°ŠŗŃŠµŃŠøŠø shigella sonnei, ŃŠæŠ¾ŃŠ¾Š± ŠµŠ³Š¾ ŠæŠ¾Š»ŃŃŠµŠ½ŠøŃ Šø Š²ŠŗŠ»ŃŃŠ°ŃŃŠøŠµ ŠµŠ³Š¾ Š²Š°ŠŗŃŠøŠ½Š° Šø ŃŠ°ŃŠ¼Š°ŃŠµŠ²ŃŠøŃŠµŃŠŗŠ°Ń ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŃ
|
AU2012272652B2
(en)
|
2011-06-24 |
2017-06-01 |
Epitogenesis Inc. |
Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
čÆŗåč”份ęéå
¬åø |
é
Ŗę°Øé
øčæę„ę¹ę³
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
WO2013043518A1
(en)
|
2011-09-22 |
2013-03-28 |
Merck Sharp & Dohme Corp. |
Imidazopyridyl compounds as aldosterone synthase inhibitors
|
JP6170932B2
(ja)
|
2011-11-07 |
2017-07-26 |
ććć«ćć£ć¹ ć¢ć¼ć²ć¼ |
ļ½ļ½ļ½ļ¼ļ¼ļ¼ļ¼ęåććć³ļ½ļ½ļ½ļ¼ļ¼ļ¼ļ¼ęåćå«ććć£ćŖć¢åå
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
EP2592137A1
(en)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
|
ES2704069T3
(es)
|
2011-12-08 |
2019-03-14 |
Glaxosmithkline Biologicals Sa |
Vacuna basada en toxinas de Clostridium difficile
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
BR112014016223A8
(pt)
|
2011-12-29 |
2017-07-04 |
Novartis Ag |
combinaƧƵes adjuvantes de proteĆnas de ligaĆ§Ć£o de fator h meningocĆ³cico
|
MX2014010011A
(es)
|
2012-02-24 |
2014-09-08 |
Novartis Ag |
Proteinas y composiciones de pilus.
|
US20150132339A1
(en)
|
2012-03-07 |
2015-05-14 |
Novartis Ag |
Adjuvanted formulations of streptococcus pneumoniae antigens
|
JP2015509963A
(ja)
|
2012-03-08 |
2015-04-02 |
ććć«ćć£ć¹ ć¢ć¼ć²ć¼ |
ļ¼“ļ½ļ½ļ¼ć¢ć“ćć¹ććå«ćę··åćÆćÆćć³
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
ŁŲ§ŁŲ²Ų± Ų§ŁŁ |
ŲŖŲ±ŁŁŲØŲ§ŲŖ ŁŲ¹ŁŲ§Ų¬ Ų§ŁŲ§ŁŲŖŁŲ§ŲØ Ų§ŁŲ³ŲŲ§Ų¦Ł Ų§ŁŲØŁŲŖŁŲ±Ł ŁŲ·Ų±Ł ŁŲŖŲŲ¶ŁŲ±ŁŲ§
|
BR112014026812A8
(pt)
|
2012-04-26 |
2022-10-04 |
Novartis Ag |
AntĆgenos e combinaƧƵes de antĆgenos
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
EP3563865A3
(en)
|
2012-05-04 |
2019-12-04 |
Pfizer Inc |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
ģģ¤ģ¼ģ“ė°ģ“ģ¤ģ¬ģ“ģøģ¤ ģ£¼ģķģ¬ |
ė¤ź° ķė “źµ¬ź· ė¤ė¹ė„-ėØė°±ģ§ ģ ķ©ģ²“ ģ”°ģ±ė¬¼
|
AU2013311702A1
(en)
|
2012-09-06 |
2015-02-19 |
Novartis Ag |
Combination vaccines with serogroup B meningococcus and D/T/P
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
ŠŠ»ŃŠŗŃŠ¾ŃŠ¼ŠøŃŠøŠŗŠ»Š°Š¹Š½ ŠŠ°Š¹Š¾Š»Š¾Š“Š¶ŠøŠŗŠ°Š»Š· Š”Š° |
ŠŠ¼Š¼ŃŠ½Š¾Š³ŠµŠ½Š½ŃŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøŃŠøŠø
|
EP3620172A1
(en)
|
2012-10-12 |
2020-03-11 |
GlaxoSmithKline Biologicals SA |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
CA2888321A1
(en)
*
|
2012-10-17 |
2014-04-24 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
US20140193451A1
(en)
*
|
2012-10-17 |
2014-07-10 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
KR20140075201A
(ko)
*
|
2012-12-11 |
2014-06-19 |
ģģ¤ģ¼ģ“ģ¼ėÆøģ¹¼ģ£¼ģķģ¬ |
ė¤ź° ķė “źµ¬ź· ė¤ė¹ė„-ėØė°±ģ§ ģ ķ©ģ²“ ģ”°ģ±ė¬¼
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
ģģ¤ģ¼ģ“ģ¼ėÆøģ¹¼ģ£¼ģķģ¬ |
ė¤ź° ķė “źµ¬ź· ė¤ė¹ė„-ėØė°±ģ§ ģ ķ©ģ²“ ģ”°ģ±ė¬¼
|
CA2899787A1
(en)
|
2013-02-01 |
2014-08-07 |
Glaxosmithkline Biologicals Sa |
Intradermal delivery of immunological compositions comprising toll-like receptor agonists
|
EP2994161B1
(en)
|
2013-05-10 |
2020-10-28 |
California Institute of Technology |
Probiotic prevention and treatment of colon cancer
|
CA2909586C
(en)
|
2013-05-15 |
2021-08-31 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
CN103386126B
(zh)
*
|
2013-06-25 |
2015-06-17 |
åäŗ¬ē§å
“ēē©å¶åęéå
¬åø |
äøē§å«č éē
ęÆęåēå¤ä»·å
ē«åę§ē»åē©
|
MX369534B
(es)
|
2013-09-08 |
2019-11-11 |
Pfizer |
Composiciones de neisseria meningitidis y sus metodos.
|
US11708411B2
(en)
|
2013-12-20 |
2023-07-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
CN105934251A
(zh)
*
|
2014-01-21 |
2016-09-07 |
č¾ē大čÆå |
čŗēé¾ēčččå¤ē³åå
¶ē¼åē©
|
WO2015123291A1
(en)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Pcsk9 vaccine and methods of using the same
|
HUE052293T2
(hu)
|
2014-02-28 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
MĆ³dosĆtott fHbp meningococcus-polipeptidek
|
EP2921856B1
(en)
*
|
2014-03-18 |
2016-09-14 |
Serum Institute Of India Private Limited |
A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
|
CN104829711B
(zh)
*
|
2014-04-08 |
2018-04-03 |
åäŗ¬å¤©ęę°čēē©ęęÆęéå
¬åø |
ččēēčččå¤ē³åå
éęä½åå
¶åŗēØ
|
CA3212723A1
(en)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Factor h binding protein variants and methods of use thereof
|
US9815886B2
(en)
|
2014-10-28 |
2017-11-14 |
Adma Biologics, Inc. |
Compositions and methods for the treatment of immunodeficiency
|
EP3034516A1
(en)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Purification of streptococcal capsular polysaccharide
|
FI3244917T3
(fi)
|
2015-01-15 |
2023-05-25 |
Pfizer |
ImmunogeenisiƤ koostumuksia pneumokokkirokotteissa kƤytettƤvƤksi
|
CN104548090B
(zh)
*
|
2015-01-27 |
2016-11-30 |
äøå½ē§å¦é¢čæēØå·„ēØē ē©¶ę |
äøē§Ī²-č”čē³äæ®é„°ēččēå¤ē³ē»åē«čåå
¶å¶å¤ę¹ę³
|
WO2016184963A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
US11331335B2
(en)
|
2015-06-10 |
2022-05-17 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
EP3109255A1
(en)
|
2015-06-26 |
2016-12-28 |
Institut National De La Recherche Agronomique |
Immunogenic composition
|
WO2017005851A1
(en)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccines for the treatment and prevention of ige mediated diseases
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
ē¾åč¼ēč”份ęéå
¬åø |
å
å«ē¶å
±č»ä¹č¢čē³ęåēč“å
ē«ę§ēµęē©ćå
å«č©²č“å
ē«ę§ēµęē©ä¹å„ēµåå½¼ēä¹ēØé
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA3005524C
(en)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
RU2021109510A
(ru)
|
2015-12-04 |
2021-04-16 |
ŠŠ°Š½Š°-Š¤Š°ŃŠ±ŠµŃ ŠŃŠ½ŃŠµŃ ŠŠ½ŃŃŠøŃŃŃŃ, ŠŠ½Šŗ. |
ŠŠ°ŠŗŃŠøŠ½Š°ŃŠøŃ Ń ŠøŃŠæŠ¾Š»ŃŠ·Š¾Š²Š°Š½ŠøŠµŠ¼ Š°Š»ŃŃŠ° 3 Š“Š¾Š¼ŠµŠ½Š° mica/b Š“Š»Ń Š»ŠµŃŠµŠ½ŠøŃ ŃŠ°ŠŗŠ°
|
CA2954892A1
(en)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
|
US11612664B2
(en)
|
2016-04-05 |
2023-03-28 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3493840B1
(en)
|
2016-08-05 |
2022-08-24 |
Sanofi Pasteur Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
MX2019001342A
(es)
|
2016-08-05 |
2019-07-04 |
Sanofi Pasteur Inc |
Composicion de conjugado de proteina-polisacarido de neumococo multivalente.
|
US20190282684A1
(en)
|
2016-09-02 |
2019-09-19 |
Glaxosmithkline Biologicals, S.A. |
Vaccines for neisseria gonorrhoeae
|
US11478538B2
(en)
|
2016-10-07 |
2022-10-25 |
Enterome S.A. |
Immunogenic compounds for cancer therapy
|
AU2017339577B2
(en)
|
2016-10-07 |
2021-12-02 |
Enterome S.A. |
Immunogenic compounds for cancer therapy
|
EP3551668A1
(en)
|
2016-12-06 |
2019-10-16 |
GlaxoSmithKline Biologicals S.A. |
Purification process for capsular polysaccharide
|
DK3570879T3
(da)
|
2017-01-20 |
2022-04-11 |
Pfizer |
Immunogene sammensƦtninger til anvendelse i pneumokokvacciner
|
JP7010961B2
(ja)
|
2017-01-31 |
2022-02-10 |
ćć”ć¤ć¶ć¼ć»ć¤ć³ćÆ |
é«čēčēµęē©ććć³ćć®ę¹ę³
|
US10259865B2
(en)
|
2017-03-15 |
2019-04-16 |
Adma Biologics, Inc. |
Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
|
WO2018169303A1
(ko)
*
|
2017-03-15 |
2018-09-20 |
ģ£¼ģķģ¬ ģģ§ķķ |
ė¤ź° ķė “źµ¬ź· ė°±ģ ģ”°ģ±ė¬¼
|
WO2018178265A1
(en)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
EP3600391A1
(en)
|
2017-03-31 |
2020-02-05 |
GlaxoSmithKline Intellectual Property Development Limited |
Immunogenic composition, use and method of treatment
|
KR20240018697A
(ko)
|
2017-06-10 |
2024-02-13 |
ģøė²¤ķøķė¼ģ“ģ¦ ģøķ¬. |
ė©“ģģģ±ź³¼ ķģķģ²“ ź²°ķ©ģ±ģ“ ź°ģ ė 2ź° ėė ė¤ź° ģ ķ©ģ²“ ė¤ė¹ė„ė„¼ ź°ģ§ ė¤ź° ģ ķ©ģ²“ ė°±ģ
|
US10729763B2
(en)
|
2017-06-10 |
2020-08-04 |
Inventprise, Llc |
Mixtures of polysaccharide-protein pegylated compounds
|
US11723966B2
(en)
|
2017-08-14 |
2023-08-15 |
Glaxosmithkline Biologicals Sa |
Methods of boosting immune responses
|
EP3720483A2
(en)
|
2017-12-06 |
2020-10-14 |
Merck Sharp&Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
EP3749358A4
(en)
|
2018-02-05 |
2022-04-20 |
Sanofi Pasteur, Inc. |
MULTIVALENT POLYSACCHARIDE-PNEUMOCOCCAL PROTEIN CONJUGATE COMPOSITION
|
IL304977A
(en)
|
2018-02-05 |
2023-10-01 |
Sanofi Pasteur Inc |
A multivalent pneumococcal protein-polysaccharide conjugate preparation
|
WO2019173438A1
(en)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions and methods for reducing serum triglycerides
|
BR112020020780A2
(pt)
|
2018-04-11 |
2021-03-02 |
Enterome S.A. |
peptĆdeos antigĆŖnicos para prevenĆ§Ć£o e tratamento do cĆ¢ncer
|
WO2019197563A2
(en)
|
2018-04-11 |
2019-10-17 |
Enterome S.A. |
Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
|
BR112020021296A2
(pt)
|
2018-04-18 |
2021-01-26 |
Sk Bioscience Co., Ltd. |
polissacarĆdeo capsular de streptococcus pneumoniae e conjugado imunogĆŖnico do mesmo
|
WO2020016322A1
(en)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
WO2020030572A1
(en)
|
2018-08-07 |
2020-02-13 |
Glaxosmithkline Biologicals Sa |
Processes and vaccines
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ćć”ć¤ć¶ć¼ć»ć¤ć³ćÆ |
å
ē«åę§å¤éćććęåå¤ē³ļ¼ćæć³ććÆč³Ŗć³ć³ćøć„ć²ć¼ćććć³ćć®ä½æēØ
|
JP2022513458A
(ja)
|
2018-12-12 |
2022-02-08 |
ć°ć©ćÆć½ć¹ćć¹ćÆć©ć¤ć³ ćć¤ćŖććøć«ć«ćŗ ć½ć·ćØć ć¢ććć |
ļ¼Æļ¼ēµååć°ćŖć³ć·ć«åć®ććć®äæ®é£¾ćć£ćŖć¢ćæć³ććÆč³Ŗ
|
CR20210333A
(es)
|
2018-12-19 |
2021-08-18 |
Merck Sharp & Dohme |
Composiciones que comprenden conjugados de polisacĆ”rido de streptococcus pneumoniae con proteĆna y sus mĆ©todos de uso
|
WO2020165711A1
(en)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
Neisseria meningitidiscompositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ćć”ć¤ć¶ć¼ć»ć¤ć³ćÆ |
ē“°čå¤ē³é”ćē²¾č£½ććććć®ę¹ę³
|
JP2022528158A
(ja)
|
2019-04-10 |
2022-06-08 |
ćć”ć¤ć¶ć¼ć»ć¤ć³ćÆ |
ć³ć³ćøć„ć²ć¼ćåč¢čē³ęåćå«ćå
ē«åę§ēµęē©ććććå«ććććććć³ćć®ä½æēØ
|
EP3956666A1
(en)
|
2019-04-18 |
2022-02-23 |
GlaxoSmithKline Biologicals S.A. |
Antigen binding proteins and assays
|
BR112021022429A2
(pt)
|
2019-05-10 |
2022-03-22 |
Glaxosmithkline Biologicals Sa |
ProduĆ§Ć£o de conjugados
|
US20230248816A9
(en)
|
2019-08-05 |
2023-08-10 |
Glaxosmithkline Biologicals Sa |
Process for preparing a composition comprising a protein d polypeptide
|
WO2021023691A1
(en)
|
2019-08-05 |
2021-02-11 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
CN115605222A
(zh)
|
2019-09-27 |
2023-01-13 |
č¾ēå
¬åøļ¼Usļ¼ |
ččēå„ēę°čē»åē©åå
¶ę¹ę³
|
MX2022004598A
(es)
|
2019-10-16 |
2022-09-23 |
Enterome S A |
Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
|
IL292494A
(en)
|
2019-11-01 |
2022-06-01 |
Pfizer |
Preparations of Escherichia coli and their methods
|
DK4021487T3
(da)
|
2019-11-15 |
2024-02-12 |
Enterome S A |
Antigene peptider til forebyggelse og behandling af b-celle malignitet
|
EP4061412A1
(en)
|
2019-11-22 |
2022-09-28 |
GlaxoSmithKline Biologicals S.A. |
Dosage and administration of a bacterial saccharide glycoconjugate vaccine
|
US20220409539A1
(en)
*
|
2019-12-30 |
2022-12-29 |
Fraunhofer Usa Inc. |
Particles for multi-dose delivery
|
AU2021224078B2
(en)
|
2020-02-21 |
2024-01-18 |
Pfizer Inc. |
Purification of saccharides
|
EP4107170A2
(en)
|
2020-02-23 |
2022-12-28 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN111588847B
(zh)
*
|
2020-05-18 |
2023-05-26 |
å¹æå·äøå»čÆ大å¦(å¹æå·äøå»čÆē ē©¶é¢) |
äøē§å«ęåē£·é
øåēčč“Øaäøē³ęåēē¼åē©åå
¶å¶å¤ę¹ę³ååŗēØ
|
US20230250142A1
(en)
|
2020-06-12 |
2023-08-10 |
Glaxosmithkline Biologicals Sa |
Dock tag system
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
ē¾åč¼ē大č„å» |
大č
øę”æčēµåē©åå
¶ę¹ę³
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
ķģ“ģ ģøģ½ķ¬ė ģ“ķ°ė |
ķė “źµ¬ź· ė°±ģ ģ ģ¬ģ©ķźø° ģķ ė©“ģģģ± ģ”°ģ±ė¬¼
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ćć”ć¤ć¶ć¼ć»ć¤ć³ćÆ |
ć³ć³ćøć„ć²ć¼ććććč¢čē³ęåćå«ćå
ē«åę§ēµęē©ććć³ćć®ä½æēØ
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
JP2024510717A
(ja)
|
2021-02-22 |
2024-03-11 |
ć°ć©ćÆć½ć¹ćć¹ćÆć©ć¤ć³ ćć¤ćŖććøć«ć«ćŗ ć½ć·ćØć ć¢ććć |
å
ē«åę§ēµęē©ćä½æēØåć³ę¹ę³
|
EP4070814A1
(en)
|
2021-04-07 |
2022-10-12 |
Lama France |
Sars-cov-2 polypeptides and uses thereof
|
PE20240090A1
(es)
|
2021-05-28 |
2024-01-16 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
ē¾åč¼ē大č„å» |
å
å«ēµåä¹č¢čé£ęåēå
ē«åēµåē©åå
¶ēØé
|
CA3237496A1
(en)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Immunogenic fusion protein compositions and methods of use thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
KR20230116601A
(ko)
|
2022-01-28 |
2023-08-04 |
ģ“ėėƼ |
ėØøģ ģ¢ķź³ģ ģģ ģ¢ķź³ģ ģ ķ© ė°©ė² ė° ģ„ģ¹
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023187127A1
(en)
|
2022-03-31 |
2023-10-05 |
Enterome S.A. |
Antigenic peptides for prevention and treatment of cancer
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|